NCT04861298

Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early Mild Symptoms of COVID-19

Completed NA Last updated 7 February 2022

What this trial tests

NA trial testing standard of care for COVID-19 as per the hospital guidelines in COVID-19 in 100 participants. Completed in 29 August 2021.

Timeline

11 January 2021

Primary endpoint
29 August 2021

29 August 2021

Quick facts

Lead sponsor	King Edward Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	11 January 2021
Primary completion	29 August 2021
Estimated completion	29 August 2021
Sites	1 location across Pakistan

Drugs / interventions tested

• standard of care for COVID-19 as per the hospital guidelines — full drug profile →
• Quercetin Phytosome (QP)

Conditions studied

• COVID-19 — all drugs for COVID-19 →

Sponsor

King Edward Medical University

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Quercetin is a flavonoid dietary supplement that occurs in many edible fruits and vegetables. It has remarkable antioxidant, anti-inflammatory, immunoprotective and antiviral properties. It is widely used to boost the body immune system against infections and keeping healthy life-style. The purpose of the present study is to investigate the potential benefits of quercetin for preventing COVID-19 disease progression and symptoms improvement in the early stage of infection.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial.
   Di Pierro F, Iqtadar S, Khan A, Ullah Mumtaz S, et al · · 2021 · cited 123× · PMID 34194240 · DOI 10.2147/ijgm.s318949
2. COVID-19 and cellular senescence.
   Schmitt CA, Tchkonia T, Niedernhofer LJ, Robbins PD, et al · · 2023 · cited 116× · PMID 36198912 · DOI 10.1038/s41577-022-00785-2
3. Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis.
   Evangelou K, Veroutis D, Paschalaki K, Foukas PG, et al · · 2022 · cited 79× · PMID 35086840 · DOI 10.1183/13993003.02951-2021
4. Biochemistry of Antioxidants: Mechanisms and Pharmaceutical Applications.
   Losada-Barreiro S, Sezgin-Bayindir Z, Paiva-Martins F, Bravo-Díaz C. · · 2022 · cited 68× · PMID 36551806 · DOI 10.3390/biomedicines10123051
5. Promising Antiviral Activities of Natural Flavonoids against SARS-CoV-2 Targets: Systematic Review.
   Kaul R, Paul P, Kumar S, Büsselberg D, et al · · 2021 · cited 61× · PMID 34681727 · DOI 10.3390/ijms222011069
6. The Therapeutic and Prophylactic Potential of Quercetin against COVID-19: An Outlook on the Clinical Studies, Inventive Compositions, and Patent Literature.
   Imran M, Thabet HK, Alaqel SI, Alzahrani AR, et al · · 2022 · cited 45× · PMID 35624740 · DOI 10.3390/antiox11050876
7. Potential Benefits of Black Chokeberry (<i>Aronia melanocarpa</i>) Fruits and Their Constituents in Improving Human Health.
   Ren Y, Frank T, Meyer G, Lei J, et al · · 2022 · cited 42× · PMID 36431924 · DOI 10.3390/molecules27227823
8. Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial.
   Di Pierro F, Khan A, Iqtadar S, Mumtaz SU, et al · · 2022 · cited 35× · PMID 36712674 · DOI 10.3389/fphar.2022.1096853